{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:12:32Z","timestamp":1761919952668},"reference-count":20,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["transplantation-proceedings.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Proceedings"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.transproceed.2014.10.037","type":"journal-article","created":{"date-parts":[[2015,1,30]],"date-time":"2015-01-30T22:19:03Z","timestamp":1422656343000},"page":"151-154","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Diffuse Alveolar Haemorrhage: A Fatal Complication After Alemtuzumab Induction Therapy in Renal Transplantation"],"prefix":"10.1016","volume":"47","author":[{"given":"W.","family":"Tahir","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Hakeem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.transproceed.2014.10.037_bib1","series-title":"Methods in molecular medicine","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1385\/1-59259-076-4:243","article-title":"From laboratory to the clinic: The story of CAMPATH-1","volume":"vol 40","author":"Hale","year":"2000"},{"key":"10.1016\/j.transproceed.2014.10.037_bib2","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1200\/JCO.2005.04.021","article-title":"Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival","volume":"23","author":"Moreton","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.transproceed.2014.10.037_bib3","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/j.1432-2277.2006.00343.x","article-title":"The evolving role of alemtuzumab (Campath-1H) for immunosuppressive therapy in organ transplantation","volume":"19","author":"Magliocca","year":"2006","journal-title":"Transpl Int"},{"key":"10.1016\/j.transproceed.2014.10.037_bib4","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1097\/01.tp.0000219235.97036.9c","article-title":"Alemtuzumab (Campath-1H): a systematic review in organ transplantation","volume":"81","author":"Morris","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2014.10.037_bib5","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1111\/j.1600-6143.2005.00822.x","article-title":"Alemtuzumab (Campath 1H) induction therapy in cadaveric kidney transplantation \u2014 efficacy and safety at five years","volume":"5","author":"Watson","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2014.10.037_bib6","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1111\/j.1600-6143.2008.02373.x","article-title":"Alemtuzumab induction and steroid-free immunosuppression in pancreas transplantation","volume":"8","author":"Muthusamy","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2014.10.037_bib7","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/sj.bmt.1705145","article-title":"Cardiac complications after haploidentical HLA-mismatched hematopoietic stem cell transplantation using in\u00a0vivo alemtuzumab","volume":"36","author":"Oshima","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.transproceed.2014.10.037_bib8","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1182\/blood-2003-07-2345","article-title":"Cardiac toxicity of alemtuzumab in patients with mycosis fungoides\/Sezary syndrome","volume":"104","author":"Lenihan","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.transproceed.2014.10.037_bib9","unstructured":"US Food and Drug Administration. FDA alert for healthcare professionals: alemtuzumab. Available at: http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm125216.htm. Accessed July 28,\u00a02014."},{"key":"10.1016\/j.transproceed.2014.10.037_bib10","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1164\/rccm.200208-792OC","article-title":"Outcomes of diffuse alveolar hemorrhage in hematopoeitic stem cell transplant recipients","volume":"166","author":"Afessa","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.transproceed.2014.10.037_bib11","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1093\/jjco\/hyu023","article-title":"Diffuse alveolar hemorrhage as a fatal adverse effect of bevacizumab: an autopsy case","volume":"44","author":"Ikeda","year":"2014","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.transproceed.2014.10.037_bib12","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1097\/01.tp.0000226066.82066.fa","article-title":"Thrombotic microangiopathy with acquired deficiency of ADAMTS 13 activity in lung transplant recipients","volume":"81","author":"Mal","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2014.10.037_bib13","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1378\/chest.07-2354","article-title":"Diffuse alveolar hemorrhage following alemtuzumab","volume":"133","author":"Sachdeva","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.transproceed.2014.10.037_bib14","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.semarthrit.2003.09.006","article-title":"Pulmonary hemorrhage in systemic lupus erythematosus","volume":"33","author":"Badsha","year":"2004","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.transproceed.2014.10.037_bib15","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/s10067-006-0355-6","article-title":"Tacrolimus as a reinforcement therapy for a patient with MPO-ANCA\u2212associated diffuse alveolar hemorrhage","volume":"26","author":"Kawasaki","year":"2007","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.transproceed.2014.10.037_bib16","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1084\/jem.126.6.989","article-title":"The role of anti-glomerular basement membrane antibody in the pathogenesis of human glomerulonephritis","volume":"126","author":"Lerner","year":"1967","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.transproceed.2014.10.037_bib17","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1172\/JCI115625","article-title":"Molecular cloning of the human Goodpasture antigen demonstrates it to be the alpha 3 chain of type IV collagen","volume":"89","author":"Turner","year":"1992","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.transproceed.2014.10.037_bib18","doi-asserted-by":"crossref","first-page":"13374","DOI":"10.1016\/S0021-9258(18)37714-7","article-title":"Identification of the Goodpasture antigen as the alpha 3(IV) chain of collagen IV","volume":"263","author":"Saus","year":"1988","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.transproceed.2014.10.037_bib19","doi-asserted-by":"crossref","first-page":"10670","DOI":"10.1074\/jbc.M611892200","article-title":"The alloantigenic sites of alpha3alpha4alpha5 (IV) collagen: pathogenic X-linked Alport alloantibodies target two accessible conformational epitopes in the alpha5NC1 domain","volume":"282","author":"Kang","year":"2007","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.transproceed.2014.10.037_bib20","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.1172\/JCI119431","article-title":"Isoform switching of type IV collagen is developmentally arrested in X-linked Alport syndrome leading to increased susceptibility of renal basement membrane to endoproteolysis","volume":"99","author":"Kalluri","year":"1997","journal-title":"J\u00a0Clin Invest"}],"container-title":["Transplantation Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134514011956?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134514011956?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T02:06:27Z","timestamp":1651111587000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041134514011956"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["S0041134514011956"],"URL":"https:\/\/doi.org\/10.1016\/j.transproceed.2014.10.037","relation":{},"ISSN":["0041-1345"],"issn-type":[{"value":"0041-1345","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diffuse Alveolar Haemorrhage: A Fatal Complication After Alemtuzumab Induction Therapy in Renal Transplantation","name":"articletitle","label":"Article Title"},{"value":"Transplantation Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transproceed.2014.10.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}